New targeted therapy eliminates cancer with zero side effects

Johannes Karges develops anti-cancer agents that work in a targeted manner, rather than adversely affecting the entire body.

Q&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 19, 2024

FDA gives nod to BrainStorm for ALS trial after Phase III flop

Share this article BrainStorm Cell Therapeutics is running the Phase IIIb trial of NurOwn in ALS as it pushes once again for approval from the

April 9, 2024

Startup that mines ‘junk DNA’ secures R&D deal with Merck

Epitopea has inked a license and research collaboration with Merck to discover new tumor-specific antigens from so-called “dark matter” DNA, which are parts of the

February 20, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.